Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 Dual CAR-T in R/R Aggressive B-cell Lymphoma
NCT07344818Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in aggressive B-cell lymphoma, sponsored by Peking University People's Hospital. Primary endpoint: Safety of CD19+CD20 CAR-T therapy at 1 year. Started Jan 2026; status: recruiting.
02
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT07344818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07344818.